Booz Allen Hamilton has extended its drift lower this week, falling another 2.5% to $73.83, but the more interesting development sits inside the short book, where the bear position has collapsed at a pace that stands out even against an already retreating trend.
Short interest dropped nearly 24% on the week to 5.7% of free float — roughly 6.9 million shares — and shed almost 19% in a single session on August 25 alone. That follows the pattern noted last week, when an August 14 spike to around 10.6 million shares was quickly covered. What's changed is the direction of travel looks more decisive now. The SI level is materially lower than at any point in the prior 30-day window. Last week's note characterised the earlier short covering as opportunistic; this week's move looks more structural. Bears are leaving, not pausing. The lending market confirms there's nothing to constrain them: borrow availability is extraordinarily loose at nearly 4,750% — over sixteen times the 52-week minimum of around 685% — meaning lendable supply completely dwarfs demand. Cost to borrow has drifted back below 0.4%, among the lowest readings of the past month. There is no squeeze pressure, and the ORTEX short score has dropped sharply from 51.6 on August 14 to 40.3 today, reflecting the same easing in short-side conviction. Options are only mildly more cautious than usual: the put/call ratio is running at 0.91, roughly 1.3 standard deviations above its 20-day average of 0.87 — a modest tilt toward protection but nowhere near alarmed.
The Street picture is more complicated. Analyst coverage is broadly cautious, with multiple firms — Goldman Sachs, Bank of America, JPMorgan, Truist, TD Cowen, and Citigroup — all trimming targets in the weeks after the Q1 print in late July. Most maintained neutral or negative ratings alongside those cuts. Goldman holds a Sell with a $65 target; BofA kept Underperform with a $75 target. Against a current price of $73.83, those two targets sit below or barely above the stock. UBS is the lone mover in the other direction, raising its target to $78 while keeping Neutral. The consensus mean target is around $85, which implies meaningful upside, but that average is being carried by a small number of bullish outliers — the Cantor Fitzgerald Overweight at $140 stands well above the pack and should be weighed accordingly. The PE stands at around 11.7x and EV/EBITDA at 9.8x — inexpensive multiples by historical standards, and the factor score framework ranks the dividend at the top of its universe. But earnings momentum is fading: the 90-day EPS momentum score has slipped to the 36th percentile.
The earnings history offers a relevant data point with Q2 results out July 24: the stock jumped 8.8% the following day and held most of that gain over the next five sessions, adding a further 5.8%. That was the catalyst for the mid-August rally. The next print is scheduled for October 30 — far enough away that it isn't yet a near-term positioning driver, but close enough to frame the current drift. With shorts actively reducing and the stock now 4.8% below the post-earnings high, the question heading into the fall is whether the sellside's cautious tone and softening EPS momentum will weigh more heavily than the valuation support and ongoing short-side retreat as October approaches.
See the live data behind this article on ORTEX.
Open BAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
